Personalis Net Income 2018-2024 | PSNL

Personalis net income from 2018 to 2024. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Personalis Annual Net Income
(Millions of US $)
2023 $-108
2022 $-113
2021 $-65
2020 $-41
2019 $-25
2018 $-20
2017 $-24
Personalis Quarterly Net Income
(Millions of US $)
2024-06-30 $-13
2024-03-31 $-13
2023-12-31 $-27
2023-09-30 $-29
2023-06-30 $-24
2023-03-31 $-29
2022-12-31 $-31
2022-09-30 $-26
2022-06-30 $-28
2022-03-31 $-28
2021-12-31 $-20
2021-09-30 $-18
2021-06-30 $-15
2021-03-31 $-12
2020-12-31 $-13
2020-09-30 $-10
2020-06-30 $-9
2020-03-31 $-9
2019-12-31 $-7
2019-09-30 $-7
2019-06-30 $-6
2019-03-31 $-6
2018-12-31
2018-09-30 $-4
2018-06-30 $-7
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.270B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00